Valerie Odegard, Ph.D., is the chief scientific officer of Silverback Therapeutics. She brings nearly 20 years of research and drug development experience to Silverback. Most recently, Dr. Odegard served as vice president of research at Juno Therapeutics, where she was responsible for discovery and translational research efforts to advance novel cancer immunotherapies into clinical development. Prior to Juno, she held research leadership positions at Novo Nordisk and Trubion, where she oversaw the discovery and preclinical development of therapeutics for oncology and inflammatory conditions. Dr. Odegard received her Ph.D. in immunobiology from Yale University.